Washington – September 23, 2026 -- Bristol Myers Squibb (BMS) has joined the Rare Access Action Project (RAAP), adding a major biopharmaceutical player to a coalition working to resolve coverage and access barriers for rare disease patients.
RAAP expands coalition with BMS to tackle patient access barriers
RAAP, a coalition of patient advocates and life sciences companies, confirmed BMS's membership as part of its ongoing effort to develop policy solutions for structural access and coverage gaps affecting rare disease patients. Michael Eging, Executive Director of RAAP, said BMS brings a long history of scientific innovation and a strong commitment to patients facing serious and complex diseases.
BMS cites patient access hurdles across oncology, hematology and neuroscience portfolios
Bristol Myers Squibb operates across oncology, hematology, immunology, cardiovascular disease and neuroscience therapeutic areas. Mary Bordoni, Executive Director of Alliance Development at BMS, said the company aims to collaborate with patient advocates and stakeholders on policies that support sustainable access to innovative medicines, noting that patients with rare and serious diseases often face significant challenges reaching needed treatments and care.
Eging: multi-stakeholder collaboration required to identify and remove access barriers
Eging said solving access challenges requires collaboration among patients, advocates, policymakers and innovators, adding that participation from companies such as BMS strengthens RAAP's ability to bring together varied perspectives from across the rare disease community. RAAP's stated priority is ensuring rare disease patients have access to the care and treatments they need.